COPENHAGEN, Oct 17 (Reuters) - Denmark’s Novo Nordisk (NOVOb.CO: Quote, Profile, Research), the world’s biggest maker of insulin, said on Wednesday it had seen no increased risk of acute pancreatitis so far in its studies of its Phase III drug candidate liraglutide.
